Balyasny Asset Management’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $33.3K | Sell |
9,154
-1,236,340
| -99% | -$4.5M | ﹤0.01% | 1914 |
|
|
2025
Q1 | $2.39M | Buy |
1,245,494
+971,042
| +354% | +$1.86M | ﹤0.01% | 1108 |
|
|
2024
Q4 | $521K | Buy |
+274,452
| New | +$521K | ﹤0.01% | 1469 |
|
|
2024
Q3 | – | Sell |
-129,896
| Closed | -$132K | – | 1920 |
|
|
2024
Q2 | $132K | Sell |
129,896
-48,897
| -27% | -$49.9K | ﹤0.01% | 1748 |
|
|
2024
Q1 | $327K | Buy |
+178,793
| New | +$327K | ﹤0.01% | 1629 |
|
|
2022
Q4 | – | Sell |
-40,606
| Closed | -$13K | – | 2295 |
|
|
2022
Q3 | $13K | Buy |
40,606
+15,972
| +65% | +$5.11K | ﹤0.01% | 2135 |
|
|
2022
Q2 | $9K | Buy |
+24,634
| New | +$9K | ﹤0.01% | 2147 |
|
|
2020
Q4 | – | Sell |
-18,947
| Closed | -$48K | – | 1120 |
|
|
2020
Q3 | $48K | Buy |
+18,947
| New | +$48K | ﹤0.01% | 1016 |
|
|
2018
Q3 | – | Sell |
-12,645
| Closed | -$126K | – | 1405 |
|
|
2018
Q2 | $126K | Sell |
12,645
-20,454
| -62% | -$204K | ﹤0.01% | 1514 |
|
|
2018
Q1 | $315K | Buy |
33,099
+21,050
| +175% | +$200K | ﹤0.01% | 1406 |
|
|
2017
Q4 | $179K | Buy |
+12,049
| New | +$179K | ﹤0.01% | 1683 |
|
|
2015
Q3 | – | Sell |
-828,357
| Closed | -$8.52M | – | 957 |
|
|
2015
Q2 | $8.52M | Buy |
828,357
+689,681
| +497% | +$7.1M | 0.05% | 338 |
|
|
2015
Q1 | $1.54M | Sell |
138,676
-90,258
| -39% | -$1M | 0.01% | 454 |
|
|
2014
Q4 | $2.67M | Buy |
+228,934
| New | +$2.67M | 0.02% | 376 |
|